Latest News

Big multiple sclerosis breakthrough: Phase 1 trial safely resets patients' immune systems and reduces attack on myelin protein

A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and dramatically reduced patients' immune systems' reactivity to myelin by 50 to 75 percent. The therapy used billions of patients' own specially processed blood cells to create tolerance to myelin, the insulating layer that forms around nerves. In MS, the immune system attacks myelin. The approach left the normal immune system intact.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Report recommends insurers use prescription monitoring data to reduce opioid abuse, deaths

  • Almost one-third of Canadian adults have experienced child abuse

  • Coming up with explanations helps children develop cause-and-effect thinking skills

  • Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches

  • Stroke treatment, outcomes improve with new initiative

  • Newly-approved brain stimulator offers hope for individuals with uncontrolled epilepsy

  • Cyber buddy is better than 'no buddy'

  • Innovation improves drowsy driver detection

  • Multiple sclerosis: Review of current treatments for physicians

  • Researchers compare hip width and sexual behavior

  •